Bronchiectasis - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the drug development landscape for the development of drug for bronchiectasis including molecules at pre-clinical, discovery, and other developmental stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as indications coverage, therapies employed, preferred route of administration, therapeutic modalities, targets for drug development, and mechanism of action.

Overview of the drug development pipeline for bronchiectasis

Bronchiectasis makes it difficult to clear mucus by damaging the walls of the airways caused by medical conditions such as an infection, pneumonia, or cystic fibrosis. This, in turn, prevents the removal of bacteria, inhaled dust, and other small particles. Some of the symptoms observed in patients suffering from bronchiectasis include fatigue, shortness of breath, or wheezing, and chronic cough with blood or phlegm. The prevalence of bronchiectasis is rising around the world and according to the reports, around 30%-50% of people with the advanced chronic obstructive pulmonary disease (COPD) are likely to develop bronchiectasis. Technavio’s market research analysts have predicted that with the introduction of medicines and chest physical therapy (CPT) as some of the most promising approaches to treat bronchiectasis, the global bronchiectasis market will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase II development stage. For instance, sponsors such as Insmed developed INS1007 and Kamada developed Inhaled AAT, which are under phase II stage. Our market research analysts have also identified the small amount of drug molecules that are developed under the discovery, phase III, pre-clinical, and phase I/II development stages.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of bronchiectasis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Aradigm
• Bayer
• Insmed

Therapeutic assessment of the drug development pipeline for bronchiectasis by preferred route of administration

• Inhalation
• Oral

The inhalation route of administration (ROA) involves the administration of drug substances through the windpipe in various gaseous and volatile forms. It has been observed that the majority of total therapeutics are being developed for inhalation administration.

Therapeutic assessment of the drug development pipeline for bronchiectasis by therapeutic modalities

• Small molecule
• Biomolecule

According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for bronchiectasis are being developed as small molecules. Small molecules are chemically manufactured active substances that are able to enter the cells easily because of their low molecular weight.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for bronchiectasis?
• What are the companies that are currently involved in the development of drug development molecules for bronchiectasis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.